公开(公告)号：US20150104471A1

公开(公告)日：2015-04-16

申请号：US14578550

申请日：2014-12-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER

IPC: A61K39/00 ,  A61K45/06

CPC classification number: A61K39/001 ,  A61K31/351 ,  A61K35/17 ,  A61K35/26 ,  A61K35/28 ,  A61K45/06 ,  A61K2039/5158

Abstract: The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject

Abstract translation: 本发明提供了一种在有需要的受试者中通过非同基因移植物给药治疗疾病的方法，而不伴随或伴有伴随的移植排斥反应。 该方法包括向受试者施用与受试者非同基因的治疗有效的移植物，并且一定剂量的耐受性细胞与受试者和移植物不同，用于预防或减少受试者的移植物排斥，从而治疗疾病 在主题

公开(公告)号：US08921582B2

公开(公告)日：2014-12-30

申请号：US14195880

申请日：2014-03-04

Applicant: Yeda Research and Development Co. Ltd. ,  Tatyana Bendikov

Inventor： Michael Bendikov ,  Ori Gidron

IPC: C07D407/14 ,  C07D307/34

CPC classification number: C07D407/14 ,  C07D307/34

Abstract: This invention is directed to oligofurans, process of preparation and uses thereof.

公开(公告)号：US20140329758A1

公开(公告)日：2014-11-06

申请号：US14341814

申请日：2014-07-27

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： JOHANNES KERKEL ,  IRUN R. COHEN ,  VARDA ROTTER ,  ANSGAR W. LOHSE ,  NETA EREZ ,  AVISHAI MIMRAN ,  NA'AMAN KAM

IPC: C07K14/435 ,  C07K7/08 ,  C07K7/06

CPC classification number: A61K39/0008 ,  A61K38/00 ,  A61K39/0005 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435

Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.

Abstract translation: 本发明涉及能够抑制真核细胞中的细胞和免疫应答反应的肽。 本发明提供了利用这些肽治疗人退行性疾病和炎症的组合物和方法。

公开(公告)号：US08877709B2

公开(公告)日：2014-11-04

申请号：US14146396

申请日：2014-01-02

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yoram Shechter ,  Matityahu Fridkin ,  Haim Tsubery

IPC: A61K38/00 ,  A61K38/28 ,  C07D207/452 ,  C07D207/416 ,  C07D403/12 ,  A61K38/26 ,  A61K47/48 ,  C07D207/404

CPC classification number: A61K47/60 ,  A61K31/7036 ,  A61K38/1709 ,  A61K38/212 ,  A61K38/22 ,  A61K38/2242 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K47/54 ,  A61K47/545 ,  C07D207/404 ,  C07D207/416 ,  C07D207/452 ,  C07D403/12

Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

公开(公告)号：US20140322241A1

公开(公告)日：2014-10-30

申请号：US14360678

申请日：2012-11-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Karina Yaniv ,  Inbal Avraham-Davidi ,  Yogev Sela

IPC: C12N15/113 ,  G01N33/574 ,  C12Q1/68 ,  C07K16/18

CPC classification number: C07K16/18 ,  A61K38/1709 ,  C07K14/775 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  C12Q1/6886 ,  G01N33/57488

Abstract: A method of treating an angiogenesis related disease or disorder in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which regulates an amount of apolipoprotein B (ApoB), and/or an ability of ApoB to transcriptionally control vascular endothelial growth factor receptor 1 (VEGFR1).

Abstract translation: 公开了在有需要的受试者中治疗血管生成相关疾病或病症的方法。 该方法包括向受试者施用治疗有效量的调节载脂蛋白B（ApoB）的量的试剂和/或ApoB转录控制血管内皮生长因子受体1（VEGFR1）的能力。

公开(公告)号：US20140312302A1

公开(公告)日：2014-10-23

申请号：US14258696

申请日：2014-04-22

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Dan ORON ,  Zvi DEUTSCH ,  Lior NEEMAN

IPC: H01L31/0352 ,  H01L31/06

CPC classification number: H01L31/035218 ,  C09K11/54 ,  C09K11/88 ,  H01L31/02322 ,  H01L31/055 ,  Y02E10/52

Abstract: The present invention is based on a unique design of a novel structure, which incorporates two quantum dots of a different bandgap separated by a tunneling barrier. Upconversion is expected to occur by the sequential absorption of two photons. In broad terms, the first photon excites an electron-hole pair via intraband absorption in the lower bandgap dot, leaving a confined hole and a relatively delocalized electron. The second absorbed photon can lead, either directly or indirectly, to further excitation of the hole, enabling it to then cross the barrier layer. This, in turn, is followed by radiative recombination with the delocalized electron.

Abstract translation: 本发明基于新颖结构的独特设计，其结合了由隧道屏障分隔的不同带隙的两个量子点。 上转换预期通过顺序吸收两个光子而发生。 在广义上，第一个光子通过下带隙点中的内部吸收激发电子 - 空穴对，留下受限的孔和相对离域的电子。 第二个吸收的光子可以直接或间接导致孔的进一步激发，使其能够穿过阻挡层。 这又是随着与离域电子的辐射复合。

公开(公告)号：US20140243393A1

公开(公告)日：2014-08-28

申请号：US14277825

申请日：2014-05-15

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran HORNSTEIN ,  Alon Chen ,  Sharon Haramati ,  Elik Chapnik

IPC: C12N15/113

CPC classification number: C12N15/113 ,  A61K31/7088

Abstract: Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND).

Abstract translation: 公开了用于制备用于治疗运动神经元疾病（MND）的药物的上调miRNA-9或miRNA-9 *的活性或量的药剂的用途。

公开(公告)号：US08779136B2

公开(公告)日：2014-07-15

申请号：US14058191

申请日：2013-10-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： David Milstein ,  Chidambaram Gunanathan

IPC: C07F9/28

CPC classification number: C07C209/16 ,  B01J31/146 ,  C07B43/04 ,  C07C213/02 ,  C07C2601/14 ,  C07D213/38 ,  C07D305/06 ,  C07D307/52 ,  C07F9/60 ,  C07F9/64 ,  C07F15/0046 ,  C07C211/07 ,  C07C211/17 ,  C07C211/27 ,  C07C217/08 ,  C07C217/58

Abstract: The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands.

公开(公告)号：US20140120126A1

公开(公告)日：2014-05-01

申请号：US14146549

申请日：2014-01-02

Applicant: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Irun R. Cohen ,  Bracha Rager-Zisman ,  Angel Porgador ,  Johannes Herkel

IPC: A61K47/48 ,  G01N33/569 ,  C07K14/005

CPC classification number: G01N33/56983 ,  A61K47/646 ,  A61K2039/6043 ,  A61K2039/64 ,  C07K14/005 ,  C12N2770/24122 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/53 ,  Y02A50/60

Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.

Abstract translation: 本发明提供了包含分离的病毒抗原肽和衍生自HSP60的T细胞表位的合成肽的改进的疫苗。 本发明包括其中肽用作佐剂以及其中肽与病毒抗原共价连接的缀合物的混合物。 已知的合成肽载体p458为合成的病毒表位和类似物提供显着改善的免疫原性。 Ec27是从HSP60衍生的新型肽，其作为混合物或共价缀合物增加了病毒抗原的免疫原性。 一些分离的病毒表位是新的，并且被要求用于诊断以及治疗或预防用途。

公开(公告)号：US20140079682A1

公开(公告)日：2014-03-20

申请号：US14058334

申请日：2013-10-21

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Dan S. TAWFIK ,  Amir Aharoni ,  Leonid Gaydukov ,  Joel L. Sussman ,  Israel Silman

IPC: C12N9/18

CPC classification number: C12N9/18 ,  A61K38/00 ,  C12N9/16 ,  Y02A50/473

Abstract: Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes.

Abstract translation: 提供了分离的多核苷酸及其编码的多肽。 这些包括与相应的野生型PON相比具有增加的，修饰的或基本上相同的底物特异性的突变的PON酶。 还提供了使用这些酶的试剂盒和方法。